Introduction: Non-chemotherapy drug-induced agranulocytosis (NCDIA) is a serious adverse reaction that significantly increases the risk of life-threatening infections. Although the association between ...

was abandoned in late-stage development in 2017 after five deaths in its clinical trial programme related to severely low white blood cells (agranulocytosis) and sepsis. Exscientia said it had ...

For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant ...

Objective: To ascertain preventable and non-preventable risk factors for adverse drug events (ADEs) in elderly inpatients at hospital admission. Patients and Methods: This was a prospective study ...

1 Division of Molecular and Genetic Medicine, Royal Hallamshire Hospital, Sheffield, UK 2 Gastroenterology and Liver Unit, Royal Hallamshire Hospital, Sheffield, UK 3 Gastroenterology Unit, John ...

Initially 2–3mg once daily; may adjust at intervals of at least 24hrs by 1mg/day. Usual range: 1–6mg/day; max 6mg/day. Elderly, debilitated, hypotensive, severe renal or hepatic impairment: 0 ...

Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's new small molecule class of degraders from the monoclonal antibody ...

Patients can be maintained in the long term on low-dose ATD, but there is still the very small risk of agranulocytosis and, as alluded to above, relapse can still occur on stopping. Many young people ...

Ewing sarcoma (ES) is an aggressive neoplasm predominantly affecting pediatric and adolescent populations. Renal involvement in ES is exceedingly rare, representing less than 1% of all renal ...

Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, ...